Novel pharmacological approaches in abdominal aortic aneurysm
Clinical Science · 14.08.2023 · 137 (15) · 1167-1194
DOI: 10.1042/cs20220795 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 10.08.2023. Verfasst von Lídia Puertas-Umbert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain. Hauptthemen laut MEDLINE: Aortic Aneurysm, Abdominal, Aortic Rupture, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 277 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Abdominal aortic aneurysm (AAA) is a severe vascular disease and a major public health issue with an unmet medical need for therapy. This disease is featured by a progressive dilation of the abdominal aorta, boosted by atherosclerosis, ageing, and smoking as major risk factors. Aneurysm growth increases the risk of aortic rupture, a life-threatening emergency with high mortality rates. Despite the increasing progress in our knowledge about the etiopathology of AAA, an effective pharmacological treatment against this disorder remains elusive and surgical repair is still the unique available therapeutic approach for high-risk patients. Meanwhile, there is no medical alternative for patients with small aneurysms but close surveillance. Clinical trials assessing the efficacy of antihypertensive agents, statins, doxycycline, or anti-platelet drugs, among others, failed to demonstrate a clear benefit limiting AAA growth, while data from ongoing clinical trials addressing the benefit of metformin on aneurysm progression are eagerly awaited. Recent preclinical studies have postulated new therapeutic targets and pharmacological strategies paving the way for the implementation of future clinical studies exploring these novel therapeutic strategies. This review summarises some of the most relevant clinical and preclinical studies in search of new therapeutic approaches for AAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain.
- CIBER de Enfermedades Cardiovasculares, ISCIII, Madrid, Spain.
- Department of Pharmacology, Therapeutics and Toxicology, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Neuroscience Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Departamento de Angiología y Cirugía Vascular del Hospital Universitari General de Granollers, Granollers, Barcelona, Spain.
- Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
ORCID-Profile: Francesc Jiménez-Altayó, María Galán, José Martínez-González
Zitieren
APA
Puertas-Umbert, L., Almendra-Pegueros, R., Jiménez-Altayó, F., Sirvent, M., Galán, M., Martínez-González, J., & Rodríguez, C. (2023). Novel pharmacological approaches in abdominal aortic aneurysm. Clinical Science, 137(15), 1167-1194. https://doi.org/10.1042/cs20220795
Vancouver
Puertas-Umbert L, Almendra-Pegueros R, Jiménez-Altayó F, Sirvent M, Galán M, Martínez-González J, et al. Novel pharmacological approaches in abdominal aortic aneurysm. Clinical Science. 2023;137(15):1167-1194. doi:10.1042/cs20220795
BibTeX
@article{PuertasUmbert2023,
author = {Puertas-Umbert, Lídia and Almendra-Pegueros, Rafael and Jiménez-Altayó, Francesc and Sirvent, Marc and Galán, María and Martínez-González, José and Rodríguez, Cristina},
title = {Novel pharmacological approaches in abdominal aortic aneurysm},
journal = {Clinical Science},
year = {2023},
volume = {137},
number = {15},
pages = {1167--1194},
doi = {10.1042/cs20220795}
}
EUVIMED